Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study

BACKGROUND: Breast cancer incidence increases with age and real-world data is essential to guide prescribing practices in the older population. The aim of this study was to collect large scale real-world data on tolerability and efficacy of palbociclib + AI in the first line treatment of ER+/HER2-ad...

Descripción completa

Detalles Bibliográficos
Autores principales: El Badri, Salma, Tahir, Bilal, Balachandran, Kirsty, Bezecny, Pavel, Britton, Fiona, Davies, Mark, Desouza, Karen, Dixon, Simon, Hills, Daniel, Moe, Maung, Pigott, Thomas, Proctor, Andrew, Shah, Yatri, Simcock, Richard, Stansfeld, Anna, Synowiec, Alicja, Theodoulou, Marianna, Verrill, Mark, Wadhawan, Anshu, Harper-Wynne, Catherine, Wilson, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569699/
https://www.ncbi.nlm.nih.gov/pubmed/34736090
http://dx.doi.org/10.1016/j.breast.2021.10.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569699/
https://www.ncbi.nlm.nih.gov/pubmed/34736090
http://dx.doi.org/10.1016/j.breast.2021.10.010

Ejemplares similares